|
Hepatic Veno-Occlusive Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation.
|
30676436 |
2020 |
|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Antithrombin III and protein C are natural anticoagulants can be considered as markers of different stages of chronic liver disease.
|
31142255 |
2020 |
|
Hepatitis B, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was the evaluation of protein C and antithrombin III in different stages of chronic hepatitis B and C and to determine their possible role as markers of liver cell damage in different clinical stages.
|
31142255 |
2020 |
|
Endothelial dysfunction
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
ATIII plays a role in FFP-mediated protection of endothelial Sdc1 expression and barrier function, making it a potential therapeutic target to mitigate HS-induced endothelial dysfunction.
|
31389906 |
2020 |
|
Spondylo-ocular syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.
|
30676436 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There are however no current studies assessing the levels and activity of protein C (PC), protein S (PS), and antithrombin III (AT III), which are essential in haemostatic regulation, in a single cohort of T2DM patients.
|
31560710 |
2019 |
|
Endocarditis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with endocarditis (N = 21), compared to controls (N = 21), presented lower antithrombin III at day 4 (p < 0.05), elevated antithrombin III at day 90 (p < 0.01), prolonged activated partial thromboplastin time at days 4 and 10 (p < 0.05), and enhanced thrombin-antithrombin complex at day 4 (p < 0.01).
|
31009118 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
It was also demonstrated that silencing SERPINC1 upregulated the expression of B‑cell lymphoma-2 (Bcl‑2)‑associated X protein and p53 mRNA and protein, and downregulated that of Bcl‑2, survivin and cyclin D1.
|
30896875 |
2019 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Exfoliation Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The concentration of complement factor 3, kininogen-1, antithrombin III and vitamin D-binding protein was increased in all eyes with PEX.
|
30842085 |
2019 |
|
Myalgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the POST group, ROM were higher at 3-4 d and muscle soreness was lower at 3 d after exercise compared with the CON group (p<0.05).
|
30814417 |
2019 |
|
Rhegmatogenous retinal detachment
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to controls, patients with PDR had significantly higher levels of thrombin-antithrombin III complex (p < 0.001), vascular endothelial growth factor (p < 0.001), D-dimer (p = 0.038) and interleukin-8 (p = 0.04), and patients with RRD group had significantly higher levels only of thrombin-antithrombin III complex (p < 0.001).
|
31833198 |
2019 |
|
Anterior myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
ApoE multiplexed with EpCAM, plg, serpinC1 and C1q provide optimal diagnostic information for EOC with AUC = 0.913 (95% confidence interval (CI) =0.848-0.957, p < 0.0001).
|
31718609 |
2019 |
|
Nasopharyngeal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was revealed that the expression levels of SERPINC1 mRNA and protein were increased in NPC tumor tissues compared with in adjacent healthy tissues.
|
30896875 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
ApoE multiplexed with EpCAM, plg, serpinC1 and C1q provide optimal diagnostic information for EOC with AUC = 0.913 (95% confidence interval (CI) =0.848-0.957, p < 0.0001).
|
31718609 |
2019 |
|
IGA Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
SERPINC1 and ICAM1 were identified as the candidate biomarkers with excellent area-under-the-curve (AUC) values (0.84) for distinguishing Uygur IgAN from normal controls.
|
30547763 |
2018 |
|
Thalassemia
|
0.010 |
Biomarker
|
group |
BEFREE |
We investigated changes in PC, protein S (PS), antithrombin III (AT III) and soluble endothelial protein C receptor (sEPCR) in thalassemia.
|
30384036 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The highest and lowest stage of lung cancer in IPF patients was estimated at III and II, respectively.
|
30114238 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The highest and lowest stage of lung cancer in IPF patients was estimated at III and II, respectively.
|
30114238 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The highest and lowest stage of lung cancer in IPF patients was estimated at III and II, respectively.
|
30114238 |
2018 |
|
Acute pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conclusion ATIII and protein C levels decreased as severity of AP increased, particularly in cases of biliary AP.
|
28222624 |
2017 |
|
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our findings suggest a place for SERPINC1 genotyping in the diagnosis of ATD.
|
28300866 |
2017 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
AT-III and MPV were analyzed in 352 patients with AF.
|
28805957 |
2017 |
|
Fetal Growth Retardation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The array identified target genes, which were further validated: angiopoetin 4 (<i>ANGPT4</i>), platelet-derived growth factor receptor α (<i>PDGFRA</i>), tumor necrosis factor superfamily member 15 (<i>TNFSF15</i>), angiogenin (<i>ANG</i>), serpin family C member 1 (<i>SERPIN1</i>), angiopoietin 2 (<i>ANGPT2</i>), and CXC motif chemokine 12 (<i>CXCL12</i>) in telomerase-immortalized microvascular endothelial cells and primary placental endothelial cells obtained from control and FGR pregnancies.
|
28408374 |
2017 |